Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Kidney cancer in 2012

New frontiers in kidney cancer research

Nature Reviews Urology volume 10, pages 70–72 (2013)Cite this article

Subjects

2012 has been an exciting year for kidney cancer research. From the FDA approval of a new targeted agent to revival of interest in immunotherapy, several interesting studies were published that generated considerable interest.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Motzer, R. J. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30, 1371–1377 (2012).

    Article  CAS  PubMed  Google Scholar 

  3. Houk, B. E. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66, 357–371 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, 44195, OH, USA

    Kriti Mittal & Brian Rini

Authors
  1. Kriti Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian Rini.

Ethics declarations

Competing interests

B. Rini declares consulting and research funding from Pfizer. K. Mittal declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mittal, K., Rini, B. New frontiers in kidney cancer research. Nat Rev Urol 10, 70–72 (2013). https://doi.org/10.1038/nrurol.2012.256

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2012.256

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing